{
    "hands_on_practices": [
        {
            "introduction": "The first step in managing any chronic condition is to accurately assess its severity and predict its course. For Chronic Kidney Disease (CKD), clinicians worldwide use the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which provide a robust framework for classification based on glomerular filtration rate and albuminuria. This exercise () will guide you through applying these fundamental principles to translate a patient's lab values into a precise stage and risk category, a core skill for clinical decision-making.",
            "id": "4775095",
            "problem": "A patient presents with a sustained reduction in estimated glomerular filtration rate (eGFR) and elevated urine albumin excretion. Using established Kidney Disease: Improving Global Outcomes (KDIGO) classification principles, derive the chronic kidney disease classification and risk tier from first principles as follows.\n\nStart from the following foundational definitions and observations:\n- Chronic kidney disease is defined by either a persistently reduced estimated glomerular filtration rate (eGFR) below $60\\,\\mathrm{mL/min/1.73\\,m^2}$ for at least $3$ months, or markers of kidney damage such as increased urine albumin excretion. Specifically, a urine albumin-to-creatinine ratio (uACR) of at least $30\\,\\mathrm{mg/g}$ sustained for at least $3$ months satisfies the kidney damage criterion.\n- The KDIGO glomerular filtration rate categories are: G1 ($\\ge 90$), G2 ($60$ to $89$), G3a ($45$ to $59$), G3b ($30$ to $44$), G4 ($15$ to $29$), and G5 ($ 15$), all in $\\mathrm{mL/min/1.73\\,m^2}$.\n- The KDIGO albuminuria categories are: A1 ($ 30\\,\\mathrm{mg/g}$), A2 ($30$ to $300\\,\\mathrm{mg/g}$), and A3 ($ 300\\,\\mathrm{mg/g}$).\n- The KDIGO risk grid stratifies the risk of chronic kidney disease progression and cardiovascular disease across the G and A categories into four ordinal tiers: low risk, moderately increased risk, high risk, and very high risk, with increasing risk as either eGFR declines or albuminuria increases.\n\nGiven the patient has an $eGFR = 38\\,\\mathrm{mL/min/1.73\\,m^2}$ persisting for $4$ months and $uACR = 120\\,\\mathrm{mg/g}$, use the above definitions to:\n1. Determine the glomerular filtration rate category $G_x$ and albuminuria category $A_y$.\n2. Infer the associated KDIGO risk tier for both chronic kidney disease progression and cardiovascular disease from the risk grid for the $(G_x, A_y)$ cell.\n\nTo yield a single numerical final answer, encode the risk tier using the following ordinal numeric mapping based on KDIGO descriptors: low risk $\\mapsto 1$, moderately increased risk $\\mapsto 2$, high risk $\\mapsto 3$, very high risk $\\mapsto 4$. Report the encoded risk tier as the final scalar value.\n\nExpress your final answer as a pure number. If rounding becomes necessary, round to four significant figures. No units are required in the final answer.",
            "solution": "The problem requires classification and risk stratification based on KDIGO definitions, then encoding the qualitative risk tier into a single scalar using a specified ordinal mapping. We proceed step by step from foundational definitions.\n\nFirst, we verify the presence of chronic kidney disease from core criteria. Chronic kidney disease is present if either $eGFR  60\\,\\mathrm{mL/min/1.73\\,m^2}$ or $uACR \\ge 30\\,\\mathrm{mg/g}$ persists for at least $3$ months. The patient has $eGFR = 38\\,\\mathrm{mL/min/1.73\\,m^2}$ persisting for $4$ months and $uACR = 120\\,\\mathrm{mg/g}$. Both the reduced eGFR and the increased uACR are sustained beyond $3$ months. Therefore, chronic kidney disease is established by definition.\n\nSecond, we classify the glomerular filtration rate category using the KDIGO $G$ categories. The value $eGFR = 38\\,\\mathrm{mL/min/1.73\\,m^2}$ lies in the interval $30$ to $44$, which corresponds to G3b by definition.\n\nThird, we classify the albuminuria category using the KDIGO $A$ categories. The value $uACR = 120\\,\\mathrm{mg/g}$ lies in the interval $30$ to $300$, which corresponds to A2 by definition.\n\nFourth, we determine the KDIGO risk tier for the cell (G3b, A2). The KDIGO risk grid is a matrix stratifying risk across eGFR categories (G1 to G5) and albuminuria categories (A1 to A3), with risk increasing as either eGFR declines or albuminuria increases. For G3b combined with A2, the grid indicates a high risk tier for both chronic kidney disease progression and cardiovascular disease. Intuitively, G3b denotes a moderate-to-severe decrease in glomerular filtration rate, and A2 denotes moderately increased albuminuria; together, these confer a high likelihood of progressive nephron loss and heightened cardiovascular risk due to systemic endothelial dysfunction, inflammation, and fluid-electrolyte perturbations typical of uremia.\n\nFinally, we encode the qualitative risk tier using the prescribed ordinal mapping. High risk is mapped to the scalar value $3$. Therefore, the encoded KDIGO risk tier for this patient is $3$.\n\nNo rounding is required because the mapping produces an exact integer. The final answer is reported as a pure number without units, as instructed.",
            "answer": "$$\\boxed{3}$$"
        },
        {
            "introduction": "A decline in kidney function has profound systemic consequences, one of the most critical being the impaired clearance of medications. This practice problem () moves from diagnosis to practical management, challenging you to apply pharmacokinetic principles to tailor a drug regimen for a patient with CKD. Calculating the correct dose and timing for a renally-cleared drug like gentamicin is a vital skill that directly impacts patient safety and therapeutic outcomes.",
            "id": "4775117",
            "problem": "An adult with Chronic Kidney Disease (CKD) and symptomatic uremia, body mass $80$ kg, is being treated with intravenous gentamicin. Due to reduced renal function, gentamicin clearance is primarily governed by glomerular filtration and is provided as a measured total body clearance of $25$ mL/min. Assume a one-compartment, well-mixed body model with first-order elimination, and an apparent volume of distribution of $0.25$ L/kg for gentamicin in this patient. The therapeutic plan is to administer gentamicin as an intravenous bolus to achieve a peak plasma concentration of $8$ mg/L immediately post-distribution, and to minimize toxicity by allowing the concentration to decline to a trough of $1.0$ mg/L immediately before the next dose.\n\nUsing only well-established pharmacokinetic principles appropriate to the one-compartment, first-order elimination model, determine:\n- The initial gentamicin dose required to achieve the stated peak, given the specified volume of distribution.\n- The dosing interval that will allow the plasma concentration to fall from the peak of $8$ mg/L to the trough of $1.0$ mg/L, given the stated clearance and volume of distribution.\n\nReport the dose in mg and the dosing interval in hours. Round each result to three significant figures. Express the final dosing interval in hours. Do not provide units in the final boxed answer; units are specified here.",
            "solution": "This problem is solved in two parts: calculating the initial dose and then the dosing interval. We use a one-compartment model with first-order elimination.\n\n**1. Calculate the Initial Dose ($D$)**\nFirst, determine the patient's total volume of distribution ($V_d$):\n$$V_d = \\text{Specific } V_d \\times \\text{Body mass} = 0.25\\,\\frac{\\text{L}}{\\text{kg}} \\times 80\\,\\text{kg} = 20\\,\\text{L}$$\nThe required intravenous bolus dose is the product of the target peak concentration ($C_{\\text{peak}}$) and the volume of distribution:\n$$D = C_{\\text{peak}} \\times V_d = 8\\,\\frac{\\text{mg}}{\\text{L}} \\times 20\\,\\text{L} = 160\\,\\text{mg}$$\nRounding to three significant figures, the dose is $160$ mg.\n\n**2. Calculate the Dosing Interval ($\\tau$)**\nThe dosing interval is the time it takes for the concentration to fall from $C_{\\text{peak}}$ to $C_{\\text{trough}}$. This depends on the elimination rate constant ($k_e$), which is the ratio of clearance ($Cl$) to volume of distribution ($V_d$). First, convert clearance to compatible units:\n$$Cl = 25\\,\\frac{\\text{mL}}{\\text{min}} \\times \\frac{60\\,\\text{min}}{1\\,\\text{hr}} \\times \\frac{1\\,\\text{L}}{1000\\,\\text{mL}} = 1.5\\,\\frac{\\text{L}}{\\text{hr}}$$\nNow calculate $k_e$:\n$$k_e = \\frac{Cl}{V_d} = \\frac{1.5\\,\\text{L/hr}}{20\\,\\text{L}} = 0.075\\,\\text{hr}^{-1}$$\nThe dosing interval $\\tau$ is given by:\n$$\\tau = \\frac{1}{k_e} \\ln\\left(\\frac{C_{\\text{peak}}}{C_{\\text{trough}}}\\right) = \\frac{1}{0.075\\,\\text{hr}^{-1}} \\ln\\left(\\frac{8}{1.0}\\right) \\approx 27.7259\\,\\text{hr}$$\nRounding to three significant figures, the dosing interval is $27.7$ hours.\n\nThe required values are an initial dose of $160$ mg and a dosing interval of $27.7$ hours.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n160  27.7\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "As CKD progresses towards uremia, the body's ability to regulate mineral balance fails, leading to a complex condition known as CKD-Mineral and Bone Disorder (CKD-MBD). This hands-on exercise () focuses on a key aspect of this disorder: the risk of vascular and soft tissue calcification due to elevated serum phosphate. By calculating the calcium-phosphate product, you will engage with a fundamental concept used to monitor and manage one of the most serious complications of advanced kidney failure.",
            "id": "4775153",
            "problem": "A patient with Chronic Kidney Disease (CKD) stage $4$ and uremia is being evaluated for risk of extra-skeletal calcification. From the law of mass action, precipitation of calcium phosphate phases is favored when the ionic product of calcium and phosphate exceeds the relevant solubility product under physiological conditions. Because direct ionic activities are not measured clinically, a simplified, dimensionally consistent risk index in routine practice uses the measured total serum calcium and phosphate concentrations and takes their product as a proxy of the ionic product. \n\nFor a patient whose measured total serum calcium is $9.0\\,\\mathrm{mg}/\\mathrm{dL}$ and whose measured serum phosphate is $6.5\\,\\mathrm{mg}/\\mathrm{dL}$, compute the exact value of this calcium–phosphate product risk index. Express the value in $\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$, but do not include units in your boxed final answer. Provide the exact value (no rounding). For clinical context, a commonly cited threshold is $55\\,\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$, above which the risk of ectopic calcification is considered to increase in CKD.",
            "solution": "The problem requires the calculation of the calcium–phosphate product, a clinical risk index used in the management of patients with Chronic Kidney Disease (CKD). This index serves as a proxy for the ionic product of calcium and phosphate in serum, with elevated levels indicating an increased risk of ectopic calcification. The calculation is based on a direct multiplication of the measured total serum concentrations of calcium and phosphate.\n\nThe problem provides the following data:\n- The total serum calcium concentration, which we denote as $C_{\\text{Ca}}$.\n- The serum phosphate concentration, which we denote as $C_{\\text{P}}$.\n\nThe specific values given for the patient are:\n- $C_{\\text{Ca}} = 9.0\\,\\mathrm{mg}/\\mathrm{dL}$\n- $C_{\\text{P}} = 6.5\\,\\mathrm{mg}/\\mathrm{dL}$\n\nThe calcium–phosphate product risk index, which we will denote as $P_{\\text{Ca-P}}$, is defined as the simple product of these two concentrations:\n$$P_{\\text{Ca-P}} = C_{\\text{Ca}} \\times C_{\\text{P}}$$\n\nTo find the value of this index, we substitute the given numerical concentrations into the formula. The calculation involves only the magnitudes of these concentrations:\n$$P_{\\text{Ca-P}} = 9.0 \\times 6.5$$\n\nThe problem requires the exact value, so the multiplication must be performed without rounding. We can execute this multiplication directly:\n$$9.0 \\times 6.5 = 9 \\times (6 + 0.5) = (9 \\times 6) + (9 \\times 0.5) = 54 + 4.5 = 58.5$$\n\nAlternatively, to ensure precision, the decimal values can be converted to fractions:\n$$9.0 = 9$$\n$$6.5 = \\frac{65}{10} = \\frac{13}{2}$$\n\nThe product is then calculated as:\n$$9 \\times \\frac{13}{2} = \\frac{117}{2} = 58.5$$\n\nBoth methods yield the same exact value of $58.5$.\n\nThe units for this product are derived from the units of the concentrations:\n$$(\\mathrm{mg}/\\mathrm{dL}) \\times (\\mathrm{mg}/\\mathrm{dL}) = \\mathrm{mg}^{2}/\\mathrm{dL}^{2}$$\n\nTherefore, the exact value of the calcium–phosphate product risk index is $58.5\\,\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$. The problem asks for the numerical value only, without units, in the final boxed answer. The computed value of $58.5\\,\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$ exceeds the contextual clinical threshold of $55\\,\\mathrm{mg}^{2}/\\mathrm{dL}^{2}$, which is consistent with the stated increased risk of calcification for this patient.",
            "answer": "$$\\boxed{58.5}$$"
        }
    ]
}